Related Experiment Video
Updated: May 5, 2026

A Multiplexed Luciferase-based Screening Platform for Interrogating Cancer-associated Signal Transduction in Cultured Cells
Published on: July 3, 2013
Targeting PI3K signaling as a therapeutic approach for colorectal cancer
Jing Zhang1, Thomas M Roberts, Ramesh A Shivdasani
1Department of Cancer Biology, Dana-Farber Cancer Institute, Harvard Medical School, and Department of Medicine, Brigham & Women's Hospital, Boston, MA 02215, USA.
Abstract:
Survival times of patients with colorectal cancer (CRC) have increased over the past decade, primarily as a result of treatment with combinations of conventional cytotoxic agents. Because CRC is commonly associated with mutations in genes that control growth factor signaling, therapies are being developed to target the products of these genes; individualized treatment might also be guided by specific mutations in tumors and by new biomarkers. Currently, targeted therapies confer limited clinical benefit; better drugs are therefore needed. Genomic studies indicate that phosphoinositide 3-kinase (PI3K) signaling is one of the most frequently deregulated pathways in several human cancers, including CRC. PI3K signaling has an important role in cancer cell proliferation, survival, motility, and metabolism and therefore could be an attractive therapeutic target. We review PI3K signaling in CRC and discuss current therapeutic approaches.
More Related Videos
Related Concept Videos
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Targeted Cancer Therapies
There are several types of targeted therapies against...
PI3K/mTOR/AKT Signaling Pathway
Pharmacogenomics: Identification of New Drug Targets

